T
Thomas Christoph
Researcher at Grünenthal GmbH
Publications - 149
Citations - 3335
Thomas Christoph is an academic researcher from Grünenthal GmbH. The author has contributed to research in topics: Analgesic & Opioid. The author has an hindex of 29, co-authored 148 publications receiving 3022 citations. Previous affiliations of Thomas Christoph include Lund University & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Thomas M. Tzschentke,Thomas Christoph,Babette-Yvonne Koegel,Klaus Schiene,Hagen-Heinrich Hennies,Werner Englberger,Michael Haurand,Ulrich Jahnel,Thomas I. F. H. Cremers,Elmar Friderichs,Jean De Vry +10 more
TL;DR: Tapentadol exhibited analgesic effects in a wide range of animal models of acute and chronic pain and its relative resistance to tolerance development may be due to a dual mode of action consisting of both MOR activation and NE reuptake inhibition.
Journal ArticleDOI
Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist
Klaus Linz,Thomas Christoph,Thomas M. Tzschentke,Thomas Koch,Klaus Schiene,Michael Gautrois,Wolfgang P. Schröder,Babette Kögel,Horst Beier,Werner Englberger,Stefan Schunk,Jean De Vry,Ulrich Jahnel,Stefanie Frosch +13 more
TL;DR: Cebranopadol, by its combination of agonism at NOP and opioid receptors, affords highly potent and efficacious analgesia in various pain models with a favorable side effect profile.
Journal ArticleDOI
Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain
TL;DR: It is concluded that buprenorphine shows a broad analgesic profile and offers the opportunity to treat different pain conditions, including neuropathic pain.
Journal ArticleDOI
Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
Thomas Christoph,Arnold Grünweller,Arnold Grünweller,Joanna Mika,Joanna Mika,Martin K.-H. Schäfer,Wade Erik,Eberhard Weihe,Volker A. Erdmann,Robert Frank,Clemens Gillen,Jens Kurreck +11 more
TL;DR: It is reported that intrathecal injection of an siRNA against the transient receptor potential vanilloid receptor 1 (TRPV1) reduced cold allodynia of mononeuropathic rats by more than 50% over a time period of approximately 5 days.
Journal ArticleDOI
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
TL;DR: The novel analgesic tapentadol combines μ‐opioid receptor agonism and noradrenaline reuptake inhibition in a single molecule and shows potent analgesia in various rodent models of pain and the relative contribution is dependent on the particular pain indication.